BIO-TECHNE CORP shareholders Q1 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 530 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q1 2023
NameSharesValueWeighting ↓
Fithian, LLC 101,020$7,494,67415.66%
Montanaro Asset Management Ltd 387,800$28,770,8824.47%
Brown Capital Management 3,262,377$242,035,7503.62%
Sandhill Capital Partners LLC 501,059$37,173,5493.56%
STONE RUN CAPITAL, LLC 89,435$6,635,1833.17%
DF DENT & CO INC 2,949,044$218,789,6103.08%
Ownership Capital B.V. 2,324,358$172,444,1203.03%
Jackson Square Partners, LLC 1,485,067$110,177,1212.98%
Summit Creek Advisors LLC 283,412$21,026,3362.74%
Spence Asset Management 111,666$8,284,5012.65%
MAIRS & POWER INC 3,025,978$224,497,2932.59%
Pembroke Management, LTD 305,005$22,628,3212.47%
Aristotle Atlantic Partners, LLC 523,186$38,815,1702.00%
Handelsinvest Investeringsforvaltning 148,000$10,9801.75%
GENEVA CAPITAL MANAGEMENT LLC 1,070,257$79,402,3441.62%
Select Equity Group, L.P. 5,640,897$418,498,1481.49%
Eversept Partners, LP 188,659$13,996,6111.22%
BAMCO INC /NY/ 5,379,492$399,104,5111.20%
Dorsey & Whitney Trust CO LLC 142,838$10,597,1520.96%

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q1 2023. To view BIO-TECHNE CORP's shareholder history, click here.